CBA-539

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals is a high-value, publicly traded biotech focused on developing breakthrough small-molecule drugs for aesthetic and chronic inflammatory conditions. Its core achievement is the development of CBL-514, a first-in-class injectable for localized fat reduction with a novel apoptosis mechanism, which has advanced into late-stage clinical trials. The company's strategy targets large, underserved markets where current treatments are inadequate, leveraging its proprietary platform and strategic base in Taiwan for global expansion.

Therapeutic Areas